Anticancer Activities of Epigallocatechin-3-gallate Against Cholangiocarcinoma Cells

Overview

Journal Onco Targets Ther

Publisher Dove Medical Press

Specialty Oncology

Date 2017 Jan 6

PMID 28053547

Citations 25

Authors

Tae Won Kwak

Su Bum Park

Hyun-Jung Kim

Young-Il Jeong

Dae Hwan Kang

Affiliations

Soon will be listed here.

Abstract

Purpose: Epigallocatechin-3-gallate (EGCG) is an antioxidant agent derived from green tea. Because it has chemopreventive and anti-invasive effect against various cancer cells, EGCG can be used to inhibit proliferation and invasion of cholangiocarcinoma (CCA) cells.

Methods: The anticancer effects of EGCG were studied using human CCA cells (HuCC-T1). Apoptosis was analyzed by Western blotting. Invasion and migration of cancer cells were assessed with Matrigel and wound healing assays. An animal tumor xenograft model of HuCC-T1 was used to study the in vivo antitumor activities of EGCG.

Results: EGCG effectively inhibited the growth of HuCC-T1 cells with no adverse effects on the viability of 293T cells. EGCG induced apoptotic cell death at 5 µg/mL concentration. It inhibited the expression of mutant p53 and induced apoptotic molecular signals such as Bax/Bcl-2, Caspase, and cytochrome C. Furthermore, EGCG dose-dependently inhibited the activity of matrix metalloproteinase (MMP)-2/9, invasion, and migration. In the animal tumor xenograft model of HuCC-T1 cells, EGCG was subcutaneously administered beside the tumor for local treatment. EGCG efficiently inhibited growth of the tumor and suppressed carcinogenic molecular signals such as Notch1, MMP-2/9, and proliferating cell nuclear antigen.

Conclusion: EGCG induced apoptosis of cancer cells without adverse effects on normal cells. EGCG inhibited growth, invasion, and migration of HuCC-T1 cells. We suggest EGCG as a promising candidate for local treatment of CCA.

Citing Articles

Cancer Prevention and Treatment with Polyphenols: Type IV Collagenase-Mediated Mechanisms.

Pawlowski W, Caban M, Lewandowska U Cancers (Basel). 2024; 16(18).

PMID: 39335164 PMC: 11430265. DOI: 10.3390/cancers16183193.

EGCG Suppresses Adipogenesis and Promotes Browning of 3T3-L1 Cells by Inhibiting Notch1 Expression.

Wang Y, Li C, Peng W, Sheng J, Zi C, Wu X Molecules. 2024; 29(11).

PMID: 38893431 PMC: 11173936. DOI: 10.3390/molecules29112555.

Bioactive nutraceuticals as G4 stabilizers: potential cancer prevention and therapy-a critical review.

Choudhury S, Kumar P, Choudhury D Naunyn Schmiedebergs Arch Pharmacol. 2023; 397(6):3585-3616.

PMID: 38019298 DOI: 10.1007/s00210-023-02857-z.

Novel Anti-Acetylcholinesterase Effect of Champ. Extracts via Experimental and In Silico Studies.

Nguyen V, Wang S, Phan T, Doan M, Phan T, Phan T Life (Basel). 2023; 13(6).

PMID: 37374064 PMC: 10305147. DOI: 10.3390/life13061281.

Cell Survival, Death, and Proliferation in Senescent and Cancer Cells: the Role of (Poly)phenols.

Sorrenti V, Buriani A, Fortinguerra S, Davinelli S, Scapagnini G, Cassidy A Adv Nutr. 2023; 14(5):1111-1130.

PMID: 37271484 PMC: 10509428. DOI: 10.1016/j.advnut.2023.05.014.

References

Thomas M . Systemic and targeted therapy for biliary tract tumors and primary liver tumors. Surg Oncol Clin N Am. 2014; 23(2):369-81. DOI: 10.1016/j.soc.2013.11.004. View

Philips B, Coyle C, Morrisroe S, Chancellor M, Yoshimura N . Induction of apoptosis in human bladder cancer cells by green tea catechins. Biomed Res. 2009; 30(4):207-15. DOI: 10.2220/biomedres.30.207. View

Lang M, Henson R, Braconi C, Patel T . Epigallocatechin-gallate modulates chemotherapy-induced apoptosis in human cholangiocarcinoma cells. Liver Int. 2009; 29(5):670-7. PMC: 3903791. DOI: 10.1111/j.1478-3231.2009.01984.x. View

Liao S, Umekita Y, Guo J, Kokontis J, Hiipakka R . Growth inhibition and regression of human prostate and breast tumors in athymic mice by tea epigallocatechin gallate. Cancer Lett. 1995; 96(2):239-43. DOI: 10.1016/0304-3835(95)03948-v. View

Min N, Kim J, Choi J, Liang W, Ko Y, Rhee S . Selective death of cancer cells by preferential induction of reactive oxygen species in response to (-)-epigallocatechin-3-gallate. Biochem Biophys Res Commun. 2012; 421(1):91-7. DOI: 10.1016/j.bbrc.2012.03.120. View

Sandhu D, Roberts L . Diagnosis and management of cholangiocarcinoma. Curr Gastroenterol Rep. 2008; 10(1):43-52. DOI: 10.1007/s11894-008-0008-9. View

Ustundag Y, Bayraktar Y . Cholangiocarcinoma: a compact review of the literature. World J Gastroenterol. 2008; 14(42):6458-66. PMC: 2773330. DOI: 10.3748/wjg.14.6458. View

Khan S, Taylor-Robinson S, Toledano M, Beck A, Elliott P, Thomas H . Changing international trends in mortality rates for liver, biliary and pancreatic tumours. J Hepatol. 2002; 37(6):806-13. DOI: 10.1016/s0168-8278(02)00297-0. View

Thomas M . Biological characteristics of cancers in the gallbladder and biliary tract and targeted therapy. Crit Rev Oncol Hematol. 2006; 61(1):44-51. DOI: 10.1016/j.critrevonc.2006.07.006. View

10.

Hoon Lim J . Cholangiocarcinoma: morphologic classification according to growth pattern and imaging findings. AJR Am J Roentgenol. 2003; 181(3):819-27. DOI: 10.2214/ajr.181.3.1810819. View

11.

Thangapazham R, Singh A, Sharma A, Warren J, Gaddipati J, Maheshwari R . Green tea polyphenols and its constituent epigallocatechin gallate inhibits proliferation of human breast cancer cells in vitro and in vivo. Cancer Lett. 2006; 245(1-2):232-41. DOI: 10.1016/j.canlet.2006.01.027. View

12.

Singh P, Patel T . Advances in the diagnosis, evaluation and management of cholangiocarcinoma. Curr Opin Gastroenterol. 2006; 22(3):294-9. DOI: 10.1097/01.mog.0000218967.60633.64. View

13.

Khan N, Bharali D, Adhami V, Siddiqui I, Cui H, Shabana S . Oral administration of naturally occurring chitosan-based nanoformulated green tea polyphenol EGCG effectively inhibits prostate cancer cell growth in a xenograft model. Carcinogenesis. 2013; 35(2):415-23. PMC: 3908746. DOI: 10.1093/carcin/bgt321. View

14.

Patel T . Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology. 2001; 33(6):1353-7. DOI: 10.1053/jhep.2001.25087. View

15.

Sartor L, Pezzato E, Dona M, DellAica I, Calabrese F, Morini M . Prostate carcinoma and green tea: (-)epigallocatechin-3-gallate inhibits inflammation-triggered MMP-2 activation and invasion in murine TRAMP model. Int J Cancer. 2004; 112(5):823-9. DOI: 10.1002/ijc.20496. View

16.

Soares K, Kamel I, Cosgrove D, Herman J, Pawlik T . Hilar cholangiocarcinoma: diagnosis, treatment options, and management. Hepatobiliary Surg Nutr. 2014; 3(1):18-34. PMC: 3955000. DOI: 10.3978/j.issn.2304-3881.2014.02.05. View

17.

Shen F, Zhang B, Feng Y, Jia Z, An B, Liu C . Current research in perineural invasion of cholangiocarcinoma. J Exp Clin Cancer Res. 2010; 29:24. PMC: 2851676. DOI: 10.1186/1756-9966-29-24. View

18.

Ramadass S, Anantharaman N, Subramanian S, Sivasubramanian S, Madhan B . Paclitaxel/epigallocatechin gallate coloaded liposome: a synergistic delivery to control the invasiveness of MDA-MB-231 breast cancer cells. Colloids Surf B Biointerfaces. 2014; 125:65-72. DOI: 10.1016/j.colsurfb.2014.11.005. View

19.

Bhuiya M, Nimura Y, Kamiya J, Kondo S, Fukata S, Hayakawa N . Clinicopathologic studies on perineural invasion of bile duct carcinoma. Ann Surg. 1992; 215(4):344-9. PMC: 1242450. DOI: 10.1097/00000658-199204000-00007. View

20.

Fujiki H, Sueoka E, Watanabe T, Suganuma M . Synergistic enhancement of anticancer effects on numerous human cancer cell lines treated with the combination of EGCG, other green tea catechins, and anticancer compounds. J Cancer Res Clin Oncol. 2014; 141(9):1511-22. DOI: 10.1007/s00432-014-1899-5. View